Kaigene Inc., a biotechnology company based in the United States and focused on developing next-generation antibody therapies for autoimmune disorders, has announced an exclusive global licensing agreement with Celltrion Inc., a leading international biopharmaceutical company. The agreement covers two of Kaigene’s nonclinical-stage assets, KG006 and KG002, allowing Celltrion to develop and commercialize these therapies worldwide, with the exception of Greater China and Japan for KG006.
Health Technology Insights: Jonathan Blackburn Joins Net Health’s Executive Team as Chief Revenue Officer
Under the terms of the collaboration, Kaigene will receive an upfront payment of $8 million and could earn up to $736 million in milestone payments if the assets reach key clinical and commercial stages. This includes $11 million in near-term milestones tied to the initiation of Phase 1 clinical trials. In addition, Kaigene is eligible for tiered royalties on net sales if the therapies are successfully commercialized. Celltrion will hold exclusive global rights for KG002 and most rights for KG006 outside specified regions.
Minjae Shin, Chief Executive Officer of Kaigene Inc., said the partnership reflects the company’s mission to advance nonclinical antibody candidates through strategic collaborations that accelerate development and global availability. He emphasized that Celltrion’s fully integrated capabilities in manufacturing, clinical development, regulatory processes, and worldwide commercialization make it an ideal partner to bring Kaigene’s innovative therapies to patients across the globe.
Health Technology Insights: Noul Supplies AI Diagnostic Platform miLab to Charité Hospital
Kaigene’s pipeline utilizes its proprietary PDEG (Pathogenic Antibody Degrader) platform to selectively remove harmful antibodies that worsen autoimmune diseases. KG006 is a next-generation FcRn inhibitor designed with a novel antibody structure to provide extended durability and best-in-class potential compared with current treatments. KG002 is a first-in-class dual-action antibody capable of selectively degrading disease-specific autoantibodies while simultaneously suppressing disease-specific B cells in certain autoimmune conditions.
This collaboration marks a significant step for Kaigene in translating its antibody discoveries into therapies that could offer new treatment options for patients with autoimmune disorders, combining Kaigene’s innovative platform with Celltrion’s global reach and development expertise.
Health Technology Insights: Nigeria Launches Initiative for Metastatic Colorectal Cancer
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
